基本信息
浏览量:3
职业迁徙
个人简介
Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). He has been a principal investigator on many of the key Global and Australian CML trials that have shaped the way tyrosine-kinase inhibitors (TKI's) are selected and sequenced. He has been a leader in the area of treatment-free remission (TFR) and influential in the recent recommendations to make TFR a mainstream goal of therapy. He has published over 300 papers with over 54,000 citations.
In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
研究兴趣
论文共 743 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Hagop Kantarjian, Susan Branford,Massimo Breccia, Jorge Cortes,Fadi G. Haddad,Andreas Hochhaus,Timothy Hughes,Ghayas C. Issa,Elias Jabbour,Franck E. Nicolini,Koji Sasaki, Francois Xavier-Mahon
Leukemiapp.1-4, (2024)
Leukemia (2024)
Leukemia (2024)
Hagop Kantarjian,Susan Branford,Massimo Breccia, Jorge Cortes,Fadi G. Haddad,Andreas Hochhaus,Timothy Hughes,Ghayas C. Issa,Elias Jabbour,Franck E. Nicolini,Koji Sasaki, Francois Xavier-Mahon
Leukemiapp.1-4, (2024)
Bloodno. Supplement 1 (2023): 450-450
HemaSphereno. S3 (2023): e907256e-e907256e
British journal of haematologyno. 6 (2023): 1127-1136
HemaSphereno. S3 (2023): e88427a9-e88427a9
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn